Vaxcyte, Inc. (PCVX): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Vaxcyte, Inc. (PCVX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. pcvx-20260617 0001649094 FALSE 825 Industrial Road Suite 300 San Carlos California 0001649094 2026-06-17 2026-06-17 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _____________________________________________ FORM 8-K _____________________________________
How this was made
The 30-second read
Why it matters
The company reports (1) Jacks Lee’s retirement from the board effective June 17, 2026 and his transition to a consulting role on global strategic supply and manufacturing operations, and (2) Moncef Slaoui’s immediate appointment as an independent Class II director with a term expiring at the 2028 annual meeting; director compensation includes an annual equity grant equivalent value set at $430,000.
Market read
Governance update with specified director compensation; no new financial targets, trial results, or material transactions were disclosed.
What to watch
Traders may overreact to board headlines; the filing lacks any new clinical, product, or supply-chain contract specifics that would drive material repricing.
Background
This is an SEC Form 8-K (Item 5.02) reporting director/officer changes and compensatory arrangements.
Ticker impact
Vaxcyte disclosed a director retirement and the immediate appointment of Moncef Slaoui to its board, plus related compensation terms.
Limited, mostly sentiment/governance-driven reaction; no direct operational or financial guidance change disclosed.
The filing is an 8-K Item 5.02 governance update (retirement, new independent director, standard indemnification, $430k annual equity grant value). It does not include earnings, guidance, financing, or material contract details.
Market effects
Minimal; governance/board updates typically do not reset sector fundamentals for biotech/healthcare tools absent accompanying operational catalysts.
Minimal; Nasdaq-listed governance disclosure with no stated regional commercial impact.
Minimal; no international regulatory, trial, or partnership details were disclosed.
Counterpoint
The consulting agreement for the retiring director could be viewed as continuity rather than a fresh strategic shift, reducing the incremental signal of the new appointment.
Key entities
- companyVaxcyte, Inc.
Nasdaq-listed company filing the 8-K reporting board and director compensation changes.
- personJacks Lee
Retiring board director effective June 17, 2026; enters a consulting agreement with the company.
- personMoncef Slaoui
Appointed independent Class II director effective immediately; director compensation per program; indemnification agreement entered.
